During an asthma attack or a chronic obstructive pulmonary disease (COPD) flare-up, the bands of muscle wrapped around your airways tighten, clamping down and restricting airflow. Salbutamol directly targets these muscle bands like a key unlocking a door. It triggers a rapid relaxation signal that forces the muscles to loosen their grip. As the airway muscles relax, the breathing tubes widen, allowing air to flow freely into and out of the lungs again, which rapidly stops wheezing and relieves chest tightness.
Developed through a rational drug design programme to create a beta-2 selective alternative to isoprenaline (isoproterenol). The researchers replaced the catechol hydroxyl group with a hydroxymethyl group, producing a compound that was highly selective for respiratory smooth muscle and resistant to degradation by catechol-O-methyltransferase (COMT).
During the 1960s, the primary bronchodilator in use was isoprenaline, a non-selective beta-agonist whose cardiac stimulation caused an epidemic of asthma-related deaths. David Jack and Roy Brittain at Allen & Hanburys (now GlaxoSmithKline) sought a safer alternative that would selectively target lung tissue. They synthesised AH-3365 in 1966, which demonstrated profound bronchodilation without significant cardiac toxicity. Marketed in the UK as Ventolin in 1969 and approved by the US FDA in 1981, salbutamol completely replaced older agents. It remains the most widely prescribed asthma medication in the world and is a cornerstone of the WHO Essential Medicines List.
Reversible airway obstruction (asthma), which remains its primary clinical application today.